SCHEMBL29550896

SCHEMBL29550896

C[C@@H](O)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](Cc1ccc(OC(C)(C)C)cc1)C(=O)NCCCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ IL23R Q5VWK5 10/20 0.57
▸ KISS1R Q969F8 7/20 0.57
▸ UTS2R Q9UKP6 1/20 0.55
▸ GHSR Q92847 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29550709 0.94 KISS1R (0.61) IL23RKISS1RUTS2RGHSR
SCHEMBL29551174 0.91 IL23R (0.59) IL23RKISS1RGHSR
SCHEMBL29550975 0.89 KISS1R (0.59) IL23RKISS1RGHSR
SCHEMBL29550927 0.89 KISS1R (0.59) IL23RKISS1RGHSR
SCHEMBL29550706 0.89 KISS1R (0.59) IL23RKISS1RGHSR
SCHEMBL29551307 0.89 GHSR (0.59) IL23RKISS1RGHSR
SCHEMBL29550674 0.88 GHSR (0.58) IL23RKISS1RGHSR
SCHEMBL29550711 0.87 GHSR (0.59) IL23RKISS1RUTS2RGHSR
SCHEMBL29550653 0.87 GHSR (0.59) IL23RKISS1RUTS2RGHSR
SCHEMBL29550892 0.86 GHSR (0.62) IL23RKISS1RUTS2RGHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220047679-A1 COMBINATION THERAPY ANTISENSE THERAPEUTICS LTD (AU) 2022-02-17 — — US claimed
US-20220047679-A1 COMBINATION THERAPY ANTISENSE THERAPEUTICS LTD (AU) 2022-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220047679-A1 COMBINATION THERAPY GHSR, GHRHR, IGF1R IL23R 1067/4885KISS1R 390/4885UTS2R 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback